Semper Paratus Acquisition Corporation (LGST): history, ownership, mission, how it works & makes money

From a Nasdaq-listed SPAC that raised $345 million in its November 8, 2021 IPO by issuing 34.5 million units at $10 apiece to a rebranded clinical-stage immunotherapy company, Semper Paratus Acquisition Corporation's journey-now trading as Tevogen Bio Holdings Inc. (ticker TVGN) after the SEC declared the registration statement effective on January 5, 2024 and the merger's completion on February 14, 2024-reads like a case study in SPAC transformation: as of Monday, December 15 at 17:15 PST the legacy LGST Class A price quoted was $0.3983 (change -$0.01, -0.01%), reflecting the market's recalibration amid a merger that valued Tevogen at $1.2 billion; led by Richard N. Peretz and Hooman Yazhari with executive team members including CEO B. Ben Baldanza and President Jeff Rogers, the combined company now focuses on off-the-shelf, genetically unmodified CD8+ T cell therapeutics using its ExacTcell platform, advancing clinical trials with reported positive safety signals while pursuing commercialization, partnerships, and a business model designed to scale affordable personalized immunotherapies for infectious diseases, cancers, and neurological disorders.

Semper Paratus Acquisition Corporation (LGST) - Intro

• Price: 0.3983 USD
• Change: -0.01 USD (-0.01%) from previous close
• Latest trade time: Monday, December 15, 17:15:00 PST

• Entity type: Special Purpose Acquisition Company (SPAC) focused on identifying and completing a business combination with one or more target companies.
• Primary activity: Raise capital via an IPO, hold proceeds in trust, seek qualifying acquisition (business combination) within a defined timeframe.
• Ticker: LGST

• IPO phase - raises funds from public investors and lists units/shares and possibly warrants.
• Trust and search phase - IPO proceeds are held in a trust account while management searches for target(s).
• Announcement and vote - Management announces a proposed business combination; shareholders typically vote to approve or redeem shares.
• Completion - If approved and closing conditions met, the SPAC merges with or acquires the target, taking it public through the reverse merger.

• Post-merger equity performance - shareholders benefit if the combined public company appreciates post-closing.
• Warrant exercise - warrants issued with units can convert to equity if the stock exceeds strike price, potentially providing additional capital to the combined company.
• Management economics - sponsors typically hold founder shares and may realize gains upon successful business combinations and secondary transactions.
• Fees and transaction-related economics - advisory, underwriting, or promote structures can create sponsor returns tied to deal completion and company performance.

• Initial investors and sponsors typically hold founder shares and may provide PIPE financing at deal announcement to support the combination.
• Public shareholders control redemptions and vote on the proposed business combination.
• Board composition and sponsor background are critical for assessing execution risk and alignment of interests.

• SEC filings (S-1, 8-K, proxy statements) provide definitive capital structure, sponsor holdings, warrant terms, trust value, and redemption mechanics.
• Real-time market quotes and trade times are available via major exchanges and market data providers; latest quote shown above.

Semper Paratus Acquisition Corporation (LGST): History

• IPO and capital raised: On November 8, 2021, LGST completed its initial public offering, raising $345.0 million by issuing 34.5 million units at $10.00 per unit.
• Public trading: In December 2021 the company began trading Class A ordinary shares and warrants separately on the Nasdaq Global Market under the symbols LGST and LGSTW.
• Target selection and deal announcement: In June 2023, LGST entered into a definitive agreement to merge with Tevogen Bio Inc., a clinical-stage specialty immunotherapy company.
• Regulatory clearance: On January 5, 2024, the SEC declared effective the registration statement for the proposed business combination.
• Completion and rebrand: The merger closed on February 14, 2024, and the combined company rebranded as Tevogen Bio Holdings Inc., with shares trading under ticker TVGN.

• Founders/sponsors: A sponsor group provided initial capital and backstop support typical for SPACs (cash in trust from IPO: $345.0 million).
• Public investors: 34.5 million public units converted into Class A shares and warrants; public shareholder redemption rights applied prior to closing.
• Post-merger ownership: ownership shifted to holders of combined equity in Tevogen Bio Holdings Inc.; sponsors' founder shares typically converted or diluted per merger terms.

• Initial mission: To identify and combine with a high-growth target where public markets can accelerate scale and access to capital.
• Deal rationale with Tevogen: Pairing LGST's capital base and public listing with Tevogen's clinical-stage immunotherapy pipeline aimed to provide funding runway for clinical development and commercialization.

• Capital formation: Raises cash from public investors via IPO (LGST raised $345.0M into a trust account).
• Search and negotiate: Management seeks a target and negotiates a definitive merger agreement (June 2023 deal announcement).
• Shareholder vote and regulatory clearance: Requires shareholder approval and SEC effectiveness of registration statement (achieved Jan 5, 2024).
• Business combination close: Combines with target; public investors either remain in the new public company or redeem shares for cash from the trust (closed Feb 14, 2024).
• Revenue generation for sponsors/investors: Sponsors profit via founder shares (typically ~20% pre-deal), potential warrant exercise, and post-merger equity appreciation if the combined company's stock outperforms the IPO price.

Semper Paratus Acquisition Corporation (LGST): Ownership Structure

• Pre-merger public listings: common shares traded under LGST and warrants under LGSTW on Nasdaq.
• Pre-merger leadership: Executive Chairman Richard N. Peretz; Vice Chairman Hooman Yazhari; CEO B. Ben Baldanza; President Jeff Rogers.
• Merger transaction: Tevogen Bio valued at $1.2 billion; Tevogen stockholders received shares equivalent to that valuation as consideration.
• Post-merger identity: combined entity operates as Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company focused on off-the-shelf, genetically unmodified T cell therapeutics.
• Post-merger listing: shares now trade on Nasdaq under the ticker TVGN, reflecting the new ownership and capital structure.

Semper Paratus Acquisition Corporation (LGST): Mission and Values

• Dedicated to developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases, cancers, and neurological disorders.
• Emphasizes providing accessible personalized immunotherapies to large patient populations rather than ultra-niche therapies limited by cost or logistics.
• Commits to overcoming cost and geography-related barriers through advanced science and innovative business models (e.g., centralized manufacturing plus regional hubs; value-based contracting).
• Leverages a proprietary ExacTcell-style platform to standardize cell selection, manufacturing, and distribution for multiple indications.
• Leadership frames accessible personalized therapeutics as the next frontier of medicine and prioritizes patient access in governance and strategy.

• Revenue models: product sales per treatment, recurring dosing where applicable, licensing and strategic partnerships.
• Cost control: streamlined allogeneic manufacturing to achieve per-dose cost targets materially below autologous alternatives (aiming for single‑digit to low‑double‑thousand USD per dose economics vs. typical tens of thousands for bespoke autologous therapies).
• Market expansion: targeting larger patient pools via off‑the‑shelf inventory reduces time-to-treatment and increases throughput, improving lifetime patient value.
• Partnerships and milestones: upfront payments, R&D funding, and milestone/license royalties from pharma or health systems accelerate non-dilutive capital inflows.

• Embed access metrics into corporate KPIs (e.g., percentage of patients treated in underserved regions, time-to-treatment targets in days).
• Adopt pricing and reimbursement strategies that enable broad payer acceptance and value-based arrangements.
• Maintain transparent reporting on clinical outcomes, safety, and real-world effectiveness to support payer coverage and clinician adoption.

Semper Paratus Acquisition Corporation (LGST): How It Works

• Platform basis: ExacTcell-an antigen-specific CD8+ T cell manufacturing and selection process designed to produce targeted, unmodified cytotoxic T cells suitable as allogeneic or broadly applicable therapeutics.
• Target indications: acute and chronic infectious diseases (e.g., viral infections), multiple cancer types (solid tumors and hematologic malignancies), and certain neuro-immune conditions where antigen-specific T cells may be therapeutic.
• Product profile: off-the-shelf (allogeneic-ready) or rapidly personalized (shared antigen panels) T cell doses that avoid complex gene-editing steps-reducing manufacturing complexity and regulatory risk relative to heavily modified cell therapies.

• Clinical trials: the company conducts proof-of-concept and early-phase clinical studies to establish safety and preliminary efficacy; public communications emphasize positive safety signals from initial proof-of-concept trials.
• Endpoints: safety/tolerability, antigen-specific T cell persistence, target biomarker reduction (viral load or tumor markers), objective response rates in oncology cohorts, and functional neurological assessments where applicable.
• Regulatory pathway: staged IND-enabling studies, Phase 1 safety cohorts, then expansion cohorts with biomarker-driven adaptive designs to accelerate development toward pivotal trials.

• Value proposition: commercially attractive pricing by avoiding costly genetic engineering steps and enabling batch manufacturing for multiple patients from selected donor pools.
• Revenue streams: direct therapy sales, milestone and licensing deals with larger biopharma partners, and potential recurring revenue from repeat-dosing regimens or maintenance products.
• Scalability: centralized GMP manufacturing with regional fill/finish hubs to reduce per-dose cost and support payor negotiations for high-demand indications.

• Safety-first design: unmodified T cells aim to reduce risks associated with gene-editing or engineered receptors.
• Affordability emphasis: simplified manufacturing and donor-bank approaches lower cost-per-dose versus bespoke autologous therapies.
• Partnering potential: platform is positioned for collaboration with larger pharma to access late-stage development and global commercialization resources.

Semper Paratus Acquisition Corporation (LGST): How It Makes Money

• De-SPAC / Business Combination Proceeds - LGST raises cash via its IPO trust account; value is realized when that capital is deployed into a target company that can grow revenues and market value post-merger.
• Equity Appreciation - Post-merger equity stakes (shares, warrants) can increase in value as the combined company achieves clinical, regulatory, or commercial milestones.
• Strategic Partnerships & Collaborations - The merged operating company pursues licensing deals, co-development, and commercialization agreements that create milestone and royalty income streams.
• Follow-on Financings - PIPEs and secondary offerings provide capital and can generate advisory/placement fees and dilution-managed upside for initial sponsors.
• Transactional Fees & Advisory - Sponsors and advisors can monetize transaction-related fees on successful deals and integrations.

• Clinical-to-commercial transition: achieving IND/CTA, pivotal trials, and regulatory approvals which unlock product sales.
• Commercial partnerships: upfront payments, R&D milestones, regulatory milestones, and tiered royalties from larger pharma partners.
• Direct product sales: hospital, clinic, and specialty center billing for autologous/allogeneic cell therapies and related services.
• Service and platform revenue: manufacturing-as-a-service (CMO), diagnostics, companion assays, and logistics for cell therapies.
• Geographic expansion and licensing to address cost and access barriers, expanding patient pools and lifetime revenue per indication.